Sagent Pharmaceuticals, Inc. (SGNT) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of $0.09, $0.10 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $69.2 million versus the consensus estimate of $67.14 million.
Sagent Pharmaceuticals, Inc. sees FY2014 revenue of $270-290 million, versus the consensus of $279.07 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- vVardis files for US IPO showing net loss, revenue growth
- Jet fuel prices near $5 per gallon in New York and Los Angeles
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
